DexCom (DXCM) Set to Announce Earnings on Thursday

DexCom (NASDAQ:DXCM) will release its earnings data after the market closes on Thursday, April 25th. Analysts expect DexCom to post earnings of $0.27 per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. DexCom’s revenue for the quarter was up 26.9% compared to the same quarter last year. During the same period last year, the firm posted $0.34 EPS. On average, analysts expect DexCom to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $133.86 on Thursday. The stock has a market capitalization of $51.61 billion, a price-to-earnings ratio of 102.18, a PEG ratio of 2.31 and a beta of 1.20. DexCom has a 12 month low of $74.75 and a 12 month high of $142.00. The firm’s 50 day simple moving average is $129.20 and its 200-day simple moving average is $116.28. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. StockNews.com raised shares of DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Citigroup raised their price objective on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Raymond James raised their price objective on DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 23rd. UBS Group raised their price objective on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Finally, Royal Bank of Canada assumed coverage on DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $141.40.

Insider Transactions at DexCom

In other news, EVP Matthew Vincent Dolan sold 1,990 shares of DexCom stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the transaction, the executive vice president now owns 42,377 shares in the company, valued at approximately $5,839,974.37. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, EVP Matthew Vincent Dolan sold 1,990 shares of DexCom stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the transaction, the executive vice president now owns 42,377 shares in the company, valued at approximately $5,839,974.37. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Jereme M. Sylvain sold 3,363 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the sale, the chief financial officer now owns 71,142 shares in the company, valued at $8,304,405.66. The disclosure for this sale can be found here. Insiders have sold a total of 189,375 shares of company stock worth $25,530,859 in the last quarter. Company insiders own 0.41% of the company’s stock.

Institutional Trading of DexCom

Several institutional investors and hedge funds have recently bought and sold shares of DXCM. Bartlett & CO. Wealth Management LLC purchased a new stake in DexCom in the 4th quarter valued at about $27,000. Harbour Investments Inc. raised its holdings in DexCom by 55.6% in the 3rd quarter. Harbour Investments Inc. now owns 336 shares of the medical device company’s stock valued at $31,000 after buying an additional 120 shares during the period. Atlas Capital Advisors LLC purchased a new stake in DexCom in the 2nd quarter valued at about $33,000. O Dell Group LLC acquired a new position in DexCom in the 4th quarter valued at about $54,000. Finally, Sunbelt Securities Inc. acquired a new position in DexCom in the 1st quarter valued at about $70,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.